Brand new: a2MC, Blackmores, H&H, and Elixinol's financials in the spotlight

Brand-new-a2MC-Blackmores-H-H-and-Elixinol-s-financials-in-the-spotlight.jpg

This round-up looks at the latest financial performance of nutraceutical and infant formula brands, including PERKii, The a2 Milk Company, Blackmores, Swisse's parent company H&H Group, and CBD specialist Elixinol.

Survive the journey: PERKii sees steady sales of probiotic drinks made with exclusive encapsulation technology 

Australian probiotic brand PERKII has seen steady sales of its probiotic beverages amid the pandemic, boosting the firm’s confidence in its overseas expansion plans.

The company manufactures still and sparkling probiotic drinks, made with an exclusive encapsulation technology which allow probiotics to survive the harsh stomach acid conditions in order to reach the gut.

Although founded in 2015, PERKii only started entering major retailers such as Woolworths in the last three years, and has seen consistent growth.

a2 Milk Company slump: Firm banks on offline and local e-commerce retail to recoup CBEC losses in China

The a2 Milk Company is banking on offline and local e-commerce retail in China to make up for its losses in daigou and cross-border e-commerce due to COVID-19, after seeing overall revenues slump by 30 per cent and profits by 79 per cent.

The ASX and NZEX listed company said revenue for FY2021 was down 30.3 per cent to NZD$1.21bn (US$837m), with net profit after tax plunged 79.1 per cent to NZD$80.7m (US$56m).

Its EBITDA margin was 10.2 per cent or 11.1 per cent – when excluding the cost of acquiring dairy nutrition firm Mataura Valley Milk, while gross margin was down to 42.3 per cent, which it said was partly due to increase in raw milk prices.

Blackmores FY2021 financials: Profit up 61% driven by growth in South East Asia and China CBEC sales

Blackmores’ FY2021 profit was up 61 per cent yoy, with South East Asia and China highlighted as regions with good growth.

Total revenue was up 1.3 per cent to AUD$575.9m (US$416.5m), while net profit after tax was up 61.2 per cent to AUD$25.4m (US$18.4m).

The rate of growth was highest in China, where revenue climbed 27.8 per cent to AUD$131.6m (US$95.2m), led by growth in the cross-border e-commerce (CBEC) channel – where sales was up 36 per cent.

H&H half-year results: Offline expansion in China and shift from daigou in ANZ yielding growth

Health and Happiness (H&H) Group said offline expansion in China, including introducing its infant formulas to more mother-and-baby stores, as well as the launch of more blue-hat certified health foods in offline trade, has pushed up its revenue for the first half of this year.

The parent company of Swisse and Biostime also said that its sales performance in Australia and New Zealand had improved, as it shifted from conducting daigou sales to China to focusing on the needs of the local ANZ markets.

In its financial results for January to June 2021, the Hong Kong Exchange (HKEX) listed company reported five per cent revenue growth to RMB$5.4bn (US$837m).

CBD, hemp specialist Elixinol to focus on Australia and US as Europe sales decline amid regulatory uncertainty

ASX-listed CBD and hemp firm Elixinol plans to focus on the Australian and US markets after reporting that sales in Europe has been on the decline due to regulatory uncertainty and COVID-19 restrictions.

The company said in its FY2021 half-year results that revenue was down 39 per cent yoy to AUD$4.8m (US$3.4m). It also incurred a loss of AUD$10.8m (US$7.7m), an 88 per cent improvement from the same period last year, where it reported a loss of AUD$90.2m (US$64.5m).

Revenue mainly came from Hemp Foods Australia, which contributed 40 per cent – AUD$1.9m (US$1.4m).